Plasma Protein Therapeutics Market Report 2026

Plasma Protein Therapeutics Market Overview

• Plasma Protein Therapeutics market size has reached to $34.68 billion in 2025 • Expected to grow to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Increasing Prevalence Of Autoimmune Disorders To Enhance Market Position • Market Trend: Innovative Products Drive Competition In The Plasma Protein Therapeutics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Plasma Protein Therapeutics Market?

Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives. The main products of plasma protein therapeutics are immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other products. Immunoglobulin refers to a component of blood plasma that contains immunoglobulins or antibodies. These are administrated through different routes of administration including intravenous, and subcutaneous and are used for various applications such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema and other applications.

What Is The Plasma Protein Therapeutics Market Growth Forecast?

The plasma protein therapeutics market size is expected to see strong growth in the next few years. It will grow to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in recombinant albumin and coagulation factors, expansion of subcutaneous administration methods, increasing healthcare expenditure in emerging markets, technological advancements in precision medicine, rising public-private collaborations for plasma collection. Major trends in the forecast period include personalized plasma protein therapy development, expansion of recombinant protein production, increasing adoption of subcutaneous administration, growing awareness of rare blood disorders, enhanced supply chain and cold chain logistics.

Global Plasma Protein Therapeutics Market Segmentation

1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications Subsegments: 1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) 2) By Albumin: Human Serum Albumin, Recombinant Albumin 3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates 4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors 5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates

What Is The Driver Of The Plasma Protein Therapeutics Market?

An increasing prevalence of autoimmune disorders is expected to propel the growth of the plasma protein therapeutics market going forward. An autoimmune disorder is a condition that emerges when the body's immune system attacks and destroys healthy body cells. Therapeutic plasma exchange is used to treat autoimmune diseases, which emerge when the body misidentifies a part of itself as foreign and produces proteins (known as autoantibodies) that attack the part of the body that is misidentified. For instance, in May 2023, a study conducted by the University of Glasgow, a UK-based public university, involving 22 million people, found that autoimmune disorders affect about 10% of the UK's population, exceeding previous estimates of 2022. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics industry going forward.

Key Players In The Global Plasma Protein Therapeutics Market

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG

Global Plasma Protein Therapeutics Market Trends and Insights

Major companies operating in the plasma protein therapeutics market are focusing on developing innovative solutions, such as lyophilized plasma formulations, to meet the rising demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that offer longer shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma, making them highly suitable for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, received approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation enables convenient pre-hospital transfusion, offering rapid availability, simplified handling, and improved stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, demonstrating Octapharma’s commitment to advancing patient care through innovative plasma-based therapies.

What Are Latest Mergers And Acquisitions In The Plasma Protein Therapeutics Market?

In June 2025, Grifols, a Spain-based provider of plasma-derived therapeutics including immunoglobulins, albumin, and clotting factors, acquired Biotest AG for an undisclosed amount. With this acquisition, Grifols aimed to gain full control over Biotest’s plasma-protein therapeutic portfolio, streamline operations, and strengthen its market position in the plasma protein therapeutics industry. Biotest AG is a Germany-based provider of plasma-derived therapies, including immunoglobulins, coagulation factors, and specialty plasma proteins.

Regional Insights

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Plasma Protein Therapeutics Market?

The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Plasma Protein Therapeutics Market Report 2026?

The plasma protein therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.